IGEN v. Roche
This article was originally published in The Gray Sheet
Executive Summary
Maryland federal appeals court affirms a 1998 preliminary injunction against Roche Diagnostics Jan. 4, enjoining the firm from marketing IGEN's Origen technology under a 1992 licensing agreement to physician office laboratories (POL), which IGEN claims Roche violated. Under the injunction, Roche is required to turn over all POL customers to IGEN and escrow all POL sales. Estimating that Roche has 200-300 POL customers generating in excess of $10 mil. in annual sales, IGEN alleges that Roche's reported $7.4 mil in escrow from 100 POL customers "does not represent all of the revenue required to be placed in escrow"
You may also be interested in...
Roche Sees Minimal Elecsys Financial Impact In Wake Of IGEN Court Order
Roche Diagnostics expects only a "small percentage" of its Elecsys line of immunoassay analyzers incorporating IGEN's Origen technology will be affected by an upcoming court-ordered transfer of Elecsys physician office laboratory accounts to IGEN.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”